Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,Applied Microbiology and Biotechnology,Biochemistry,General Medicine,Bioengineering,Biotechnology
Reference78 articles.
1. Non-Small Cell Lung Cancer Treatment. (2023). National Cancer Institute. https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq.
2. Riely, G. J., Marks, J. L., & Pao, W. (2009). KRAS mutations in non-small cell lung cancer. Annals of the American Thoracic Society, 6(2), 201–205. https://doi.org/10.1513/pats.200809-107lc
3. Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & Varmus, H. E. (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLOS Medicine, 2(1), e17. https://doi.org/10.1371/journal.pmed.0020017
4. Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011). RAS oncogenes: Weaving a tumorigenic web. Nature Reviews Cancer, 11(11), 761–774. https://doi.org/10.1038/nrc3106
5. Ghimessy, Á., Radeczky, P., Laszlo, V., Hegedus, B., Rényi-Vámos, F., Fillinger, J., Klepetko, W., Lang, C. B., Dome, B., & Megyesfalvi, Z. (2020). Current therapy of KRAS-mutant lung cancer. Cancer and Metastasis Reviews, 39(4), 1159–1177. https://doi.org/10.1007/s10555-020-09903-9